Optimal immunosuppression to prevent chronic allograft dysfunction

Kidney International

Volumn 78, Issue SUPPL. 119, 2010, Pages

  Grinyó, Josep M ^a   Bestard, Oriol ^a   Torras, Joan ^a   Cruzado, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

chronic allograft dysfunction; immunosuppression

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; CHRONIC ALLOGRAFT DYSFUNCTION; CHRONIC ALLOGRAFT NEPHROPATHY; CONFERENCE PAPER; GRAFT DYSFUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 78649665848     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.426     Document Type: Conference Paper

References (37)

1. Marcén R, Fernández-Rodriguez A, Rodŕguez-Mendiola N et al. Evolution of rejection rates and kidney graft survival: a historical analysis. Transplant Proc 2009; 41: 2357-2359.
2. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006: 1-27.
3. Briganti EM, Russ GR, McNeil JJ et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-109.
4. Lee PC, Zhu L, Terasaki PI et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568-574.
5. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
6. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
7. Ekberg H, Grinyó J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560-570.
8. Smak Gregoor PJ, van Gelder T, van Besouw NM et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143-148.
9. Smak Gregoor PJ, de Sévaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373.
10. Abramowicz D, Manas D, Lao M et al. Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725-1734.
11. Abramowicz D, Del Carmen Rial M, Vitko S et al. Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234-2240.
12. Ekberg H, Tedesco-Silva H, Demirbas A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
13. Grinyó JM, Ekberg H, Mamelok RD et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009; 24: 2269-2276.
14. Frei U, Daloze P, V́tko S et al. Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. Clin Transplant 2010; 24: 500-509.
15. Demirbas A, Hugo C, Grinyó J et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transpl Int 2009; 22: 1172-1181.
16. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
17. Moore J, Middleton L, Cockwell P et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009; 87: 591-605.
18. Mulay AV, Hussain N, Fergusson D et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1756.
19. Ruiz JC, Campistol JM, Grinyó JM et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78: 1312-1318.
20. Mota A, Arias M, Taskinen EI et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961.
21. Oberbauer R, Segoloni G, Campistol JM et al. Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22-28.
22. Salvadori M, Scolari MP, Bertoni E et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194-1202.
23. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15.
24. Schena FP, Pascoe MD, Alberu J et al. Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
25. Bemelman FJ, de Maar EF, Press RR et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009; 88: 421-428.
26. Budde K, Klempnauer J, Arns W et al. Renal function, efficacy and safety of everolimus (Rad)/enteric-coated mycophenolate sodium (Ec-Mps) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study. Transplantation 2008; 86Issue 2S: 93.
27. Pearson TC, Wali R, Shidban H et al. Spare-the-nephron (stn) trial: one-year interim efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients. Am J Transplant 2006; 6(Suppl2): 432.
28. Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal trans-plant recipients. J Am Soc Nephrol 2008; 19: 1225-1232.
29. Büchler M, Caillard S, Barbier S et al. SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531.
30. Lebranchu Y, Thierry A, Toupance O et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115-1123.
31. Servais A, Meas-Yedid V, Toupance O et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552-2560.
32. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
33. Vincenti F, Larsen C, Durrbach A et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
34. Durrbach JM, Pestana T, Pearson F et al. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study) (p 547-557 ). Published Online: 16 Feb 2010.
35. Vincenti F, Charpentier B, Vanrenterghem Y. A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) (p 535-546 ). Published Online: 16 Feb 2010.
36. Bestard O, Nickel P, Cruzado JM et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19: 1419-1429.
37. Dinavahi R, Heeger PS. T-cell immune monitoring in organ transplantation. Transplantation 2009; 88: 1157-1158.